I'm Calling It: Hims & Hers Health Will Soar 56% by the End of 2026

Hims & Hers is projected to generate $3.99 billion of 2027 revenue versus $3.21 billion expected in 2026; valuing it at 2.5x forward sales implies a $42.76 share price, or 55.7% upside from $27.47. Q2 revenue rose 38% year over year to $753 million, supported by 19% subscriber growth to 2.9 million and a 21% increase in monthly revenue per subscriber to $92. However, U.S. revenue grew only 16%, gross margin fell 12 percentage points to 64%, and adjusted EBITDA declined 26.7% to $60.3 million, making margin stabilization critical to the bullish case.

Analysis

The relevant debate is not the sales multiple but whether HIMS can retain enough gross profit on incremental weight-loss and acquired international revenue to convert subscriber scale into durable EBITDA. A lower-margin mix raises fulfillment, clinical, and marketing intensity simultaneously; if contribution margin is falling, revenue growth can mechanically increase cash needs rather than operating leverage. The market is likely to re-rate the stock on two KPIs at the next 1-2 earnings prints: sequential gross-margin stabilization and marketing expense as a percentage of revenue.

The underappreciated downside is that direct-to-consumer GLP-1 economics are vulnerable to branded-drug availability, compounding enforcement, and customer churn once promotional pricing resets. HIMS also faces an adverse selection problem: higher-acuity weight-loss users may generate more clinical and fulfillment cost than the legacy sexual-health/hair-loss base. This makes the multiple more comparable to a volatile consumer subscription platform than to a scaled software-enabled healthcare business, limiting upside absent proof of sustained cohort profitability.

Consensus may be too focused on a binary margin-recovery narrative. If management can demonstrate that newer cohorts maintain revenue per subscriber while gross margin bottoms, HIMS could compound revenue at a premium multiple because its cross-sell engine reduces customer-acquisition cost versus single-condition competitors. Conversely, another material gross-margin decline or EBITDA-guide cut would likely trigger a rapid de-rating, since the current valuation framework leaves little protection from a shift in the quality of revenue.

Key Decisions for Investors

• Maintain a neutral-to-underweight HIMS stance into the next earnings release; upgrade only if gross margin is flat-to-up sequentially and adjusted EBITDA margin stabilizes. A further 300-500 bp sequential gross-margin decline would falsify the operating-leverage thesis and supports a tactical short.
• For a defined-risk bearish expression over the next 1-3 months, consider HIMS put spreads struck roughly 10-20% below spot, funded only after any pre-earnings rally. The catalyst is a margin or guidance miss; risk is a credible profitability inflection and continued subscriber monetization.
• If margin stabilization is verified, initiate a 6-12 month long HIMS position rather than underwriting a sales-multiple rerating today. Target a 2:1 reward/risk framework, with a stop tied to a renewed EBITDA guidance reduction rather than daily share-price volatility.
• Watch GLP-1 regulatory developments, branded-drug supply normalization, and management disclosure on weight-loss cohort retention. These are more decision-relevant than headline subscriber growth and could alter unit economics before reported revenue slows.